Committed to Changing Tomorrow
for the Cancer Community
There are over 14 million cancer patients and survivors living in the United States and that number is only expected to grow*. In the U.S., Astellas Oncology is dedicated to enhancing the lives of those impacted by cancer through continued development of targeted treatments and support solutions for patients and their caregivers.
Providing Treatment Options to Patients and Providers Nationwide
Astellas has a proud heritage of developing and successfully launching innovative prescription medicines, both on our own and in collaboration with partners. Furthermore, Astellas Oncology is committed to reducing the burden of care through comprehensive patient assistance programs and access services for eligible patients.
We're proud to currently offer pharmaceutical treatment options for prostate, non-small cell lung and pancreatic cancer to patients and healthcare providers in the United States:
Developing Therapies for Patients with Unmet Needs
Investigating treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
Astellas is investigating a tyrosine kinase inhibitor in a clinical setting for the treatment of relapsed or refractory AML patients who are FLT3+. This compound exhibits potent inhibitory activity against FLT3-ITD, FLT3-TKD and AXL.View MOA video
Exploring treatment of Advanced Non-Small Cell Lung Cancer
Astellas is investigating a treatment for patients with advanced non-small cell lung cancer harboring activating and drug-resistant T790M mutations. This compound irreversibly binds mutated EGFR and the T790M mutation, inhibiting unregulated cell proliferation.View MOA video
The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for uses being investigated.
Discovering the Next Generation of Antibody Drug Conjugates (ADC)
The scientists at Agensys, an affiliate of Astellas Pharma, Inc., are experts in the technology of antibody-drug conjugates (ADC) and are developing a pipeline of naked and ADC therapeutic antibodies directed at a variety of cancer types, including those of the prostate, kidney, pancreas, ovary, bladder, lung, colon, breast, skin and blood.
Astellas Employees Making a Difference
In addition to bringing innovative new medicines to patients, our commitment to changing
tomorrow places importance on the impact that Astellas employees can make within the
communities where we work and live.
Matching Gifts Program
Astellas matches employee contributions dollar for dollar to increase their impact to many organizations, including the American Cancer Society. Since the program began in 2009, employee contributions and Astellas' match to these organizations have totaled nearly $1 million.
Five Volunteer Days
Astellas provides five paid days off to full-time employees to volunteer time in the community. In 2013 alone, Astellas employees volunteered 623 days with many organizations including LUNGevity, ZERO - The End of Prostate Cancer and Us TOO International.
Changing Tomorrow Day
Astellas' annual Changing Tomorrow Day initiative underscores Astellas' dedication to making a difference in our local communities. Astellas affiliates around the globe dedicate an entire day to participate in organized, local community service. In the Americas, over 1,900 employees participated in 2014.